Key result
Shuxin Shengmai Dan protected rats from myocardial ischemia-reperfusion injury by downregulating the TLR4/NF-κB pathway and inhibiting inflammation.
Why the study?
Shuxin Shengmai Dan is used to treat angina pectoris, but its cardioprotective mechanism involving inflammation inhibition remains poorly understood.
Does Shuxin Shengmai Dan (SXSMD) prevent myocardial ischemia-reperfusion injury in rats?
Does Shuxin Shengmai Dan (SXSMD) prevent myocardial ischemia-reperfusion injury in rats?
Shuxin Shengmai Dan protects against myocardial ischemia-reperfusion injury in a rat model by inhibiting inflammation via the TLR4/NF-κB pathway.
Answers are grounded in this paper and cite their sources.
Should not alter clinical practice; leaves open translational studies of Shuxin Shengmai Dan in human ischemia-reperfusion injury.
Background: The traditional Chinese medicine Shuxin Shengmai Dan (SXSMD) is clinically used to treat angina pectoris. The mechanism of action of SXSMD protection of the heart involves inhibition of inflammation and remains poorly understood. The role of SXSMD in rats with myocardial ischemia reperfusion (IR) and the mechanism of SXSMD action were studied in this research.Methods: The rats were treated with SXSMD (3.38, 6.76, and 13.52 g/kg/day, p.o.) or Danshen injecta (1.8 mL/kg/day, p.o.) for 15 days, then the coronary arteries were ligated. Cardiac function was evaluated by electrocardiography and hemodynamic measurements. Hematoxylin-eosin (H&E) staining was used to detect pathological changes in ischemic myocardial sections. Transmission electron microscopy (TEM) was used to assess the ultrastructure of cardiomyocytes. The changes in IL-6 and TNF-α in the rat serum were detected by ELISA. The changes in the expression levels of HMGB1, TLR4, MyD88, and NF-κB mRNAs and proteins related to the TLR4/NF-κB pathway in myocardial tissue were detected by qPCR and Western blot, respectively.Results: Rats with coronary artery ligation had abnormal cardiac function, inflammatory infiltration of myocardial cells, disordered myocardial fiber arrangement, accumulation of mitochondria, and disordered muscle fibers and sarcomeres according to electron microscopy. The levels of the expression of mRNAs and proteins in myocardial tissue of the SXSMD group were decreased compared with those in the MIRI group. The serum levels of IL-6 and TNF-α were decreased. SXSMD treatment can inhibit the inflammatory response and downregulate the TLR4/NF-κB pathway in cardiomyocytes.Conclusion: SXSMD protects the rats from myocardial ischemia-reperfusion injury in the MIRI model by downregulating the TLR4/NF-κB pathway to inhibit inflammation.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2020) studied Myocardial ischemia-reperfusion injury (MIRI) (n=56). Shuxin Shengmai Dan (SXSMD) vs. Danshen injecta or no treatment (MIRI model) was evaluated on Myocardial ischemia-reperfusion injury and inflammatory response (TLR4/NF-κB pathway). Shuxin Shengmai Dan protected rats from myocardial ischemia-reperfusion injury by downregulating the TLR4/NF-κB pathway and inhibiting inflammation.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: